Excellus

A nonprofit independent licensee of the Blue Cross Blue Shield Association

Medication Assurance Program

If you are enrolled in a health benefit plan administered by Excellus BlueCross BlueShield where the Medication Assurance Program benefit applies:

The following drugs were preliminarily approved through the accelerated approval pathway by the U.S. Food and Drug Association (FDA). At this time, these drugs have unconfirmed clinical benefit and **will not be covered under prescription drug benefits or medical benefits**. Drug manufacturers of the drugs listed below are required to conduct clinical studies to prove clinical benefit in order to achieve traditional/final FDA approval. These drugs will continue to be monitored and remain uncovered until clinical benefits are proven and confirmed by criteria set forth by the FDA.

- AMONDYS 45*
- AMTAGVI*
- ARIKAYCE
- AVLAYAH*
- AVMAPKI / FAKZYNJA
- BELEODAQ*
- BEQALZI
- BIZENGRI*
- COLUMVI*
- DANYELZA*
- ELREXFIO*
- EMRELIS*
- ETCAMAH
- EXONDYS 51*
- FOLOTYN*
- FORZINITY
- GENGLYCOS*
- HEPCLUDEX
- HERNEXEOS
- IQIRVO
- KEBILIDI*
- KRESLADI*
- LIVDELZI
- LOARGYS*
- LUNSUMIO/LUNSUMIO VELO*
- LYNOZYFIC*
- LYTGOBI
- MODEYSO
- NORTHERA
- OJEMDA
- OXBRYTA
- PRALATREXATE*
- QALSODY*
- REZDIFFRA
- SKYSONA*
- TALVEY*
- TAZVERIK
- TUDRIQEV*
- VANRAFIA
- VILTEPSO*
- VONJO
- VOXZOGO
- VYONDYS 53*
- ZENBEXUS
- ZYNLONTA*

If you have questions regarding your drug coverage, please contact customer care at the number on the back of your card.

*Medical benefit drug

Updated 10/01/2026